



Republic of the Philippines

DEPARTMENT OF SCIENCE AND TECHNOLOGY



CALL FOR APPEALS ON THE PRELIMINARY RECOMMENDATION OF THE HEALTH TECHNOLOGY ASSESSMENT (HTA) COUNCIL ON CEREBROLYSIN

As of 17 March 2023, the Health Technology Assessment Council (HTA Council) has completed the assessment and deliberation for the **preliminary recommendation** on *cerebrolysin* 215.2 mg/ml, 10ml ampule for IV infusion in combination with rehabilitation or standard of care for the treatment of adults post-ischemic stroke.

The HTA Council hereby makes public its **preliminary recommendation for the non-government financing of *cerebrolysin* 215.2 mg/ml, 10ml ampule for IV infusion through its non-inclusion in the Philippine National Formulary (PNF).**

Supporting studies that informed the recommendation of HTA Council can be found in the evidence summary accessible through this link: bit.ly/CerebrolysinES. **All comments, inputs, and/or appeals may be submitted until 31 March 2023**, for the consideration of the HTAC, through email at hta@doh.gov.ph.

Please use the prescribed form for appeals indicated in the HTA Philippines website [hta.doh.gov.ph/topic-nomination/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you have any questions or concerns regarding the preliminary recommendation, please do not hesitate to contact us via email at hta@doh.gov.ph or via telephone call via 8875-7734 local 260. Thank you very much and best regards.

ANNE JULIENNE GENUINO-MARFORI, RPh, MSc

Division Chief

Health Technology Assessment Division